Glucon Welcomes Mr. Ephraim Heller to the Company's Board of Directors and Professor Adam Heller to Glucon's Scientific Advisory Board.BOULDER, Colo. -- Glucon (www.glucon.com) developer of a continuous, noninvasive, glucose monitoring glucose monitoring Lab medicine The periodic evaluation of any analyte abnormal in Pts with DM, to assess short and long-term control with antiglycemic agents. See Glucose, Glycated hemoglobin. technology for home and clinical use, announced today that Mr. Ephraim Heller is the newest member of Glucon's Board of Directors and Professor Adam Heller has joined the Company's scientific advisory board. Mr. Ephraim Heller is currently the CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. and Chairman of AngioScore. He is the founder of Therasense, Inc., established in 1996, to develop and globally market systems for diabetes management including FreeStyle(TM), a glucose monitoring device that requires a miniscule min·is·cule adj. Variant of minuscule. Adj. 1. miniscule - very small; "a minuscule kitchen"; "a minuscule amount of rain fell" minuscule , painlessly obtained, blood sample to test blood sugar levels. Therasense, Inc. went public in 2001 at a $700 million valuation and was acquired by Abbott Laboratories in 2004 for $1.3 billion. Mr. Heller is also a co-founder of E. Heller & Company, which successfully developed photocatalyst technology. Mr. Heller holds an MBA MBA abbr. Master of Business Administration Noun 1. MBA - a master's degree in business Master in Business, Master in Business Administration from Yale University and a B.A. in Physics from Harvard University. "Though at present there is a long list of companies developing glucose monitoring systems, Glucon is the company to watch. The technology is brilliant and the team dedicated and astute. I believe Glucon will make a true and lasting contribution to the treatment of diabetes," said Mr. Heller. Professor Adam Heller is the father of Ephraim Heller as well as a series of notable scientific advancements. He is the creator of the lithium thionyl chloride battery, used worldwide in medical and communications systems. He is also a co-founder of Therasense, Inc., now Abbot Diabetes Care. The company's continuous glucose monitor is based on Professor Heller's work on electrical connection ("wiring") of redox redox (rē`dŏks): see oxidation and reduction. centers of enzymes to electrodes through electron-conducting water swollen gels and has been submitted to the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. for pre-marketing approval. Professor Heller is the author of 230 papers and 84 issued U.S. patents, 46 of which represent a major part of the technology of TheraSense. Professor Heller is also the recipient of many awards including: the Grahame Award of The Electrochemical electrochemical /elec·tro·chem·i·cal/ (-kem´i-k'l) pertaining to interaction or interconversion of chemical and electrical energies. e·lec·tro·chem·i·cal adj. Society, the Battery Research Award of the Electrochemical Society, the Chemistry of Materials Award of the American Chemical Society The American Chemical Society (ACS) is a learned society (professional association) based in the United States that supports scientific inquiry in the field of chemistry. Founded in 1876 at New York University, the ACS currently has over 160,000 members at all degree-levels and in and the Reilly Award of the Electroanalytical Society. He earned his Ph.D. from Hebrew University in Jerusalem. "Glucon is developing a next generation of glucose monitoring technology, which is likely to set a new standard for the treatment of diabetes in the future," said Professor Heller. Glucon's flagship product, the Glucose Monitoring Watch (GMW GMW abbr. gram-molecular weight ), currently under development, reads glucose (sugar) levels directly from a blood vessel blood vessel n. An elastic tubular channel, such as an artery, a vein, a sinus, or a capillary, through which the blood circulates. blood vessel(s), n the network of muscular tubes that carry blood. . This is achieved by combining photo acoustics with an advanced, proprietary, spectroscopy technology. The company's prototype device is currently undergoing extensive clinical trials. Preliminary results compare favorably with conventional invasive blood glucose blood glucose Diabetology The principal sugar produced by the body from food–especially carbohydrates, but also from proteins and fats; glucose is the body's major source of energy, is transported to cells via the circulation and used by cells in the presence tests. It is estimated that by the close of 2010, 24 million people in the U.S. and 220 million worldwide will suffer from diabetes. "Both Adam and Ephraim Heller are the perfect additions to the already prestigious Glucon Board of Directors and Scientific Advisory Board. They are both industry pioneers with an intricate understanding of how to develop viable and credible technologies for the treatment of diabetes. True visionaries, with a particularly keen business sense, it is an honor to have scientists and entrepreneurs of Adam and Ephraim Heller's caliber and experience to help guide Glucon into what we believe will be an exciting and successful future," said Glucon CEO Mr. Daniel Goldberger. About Glucon Glucon, developer of a continuous, non-invasive, blood glucose (sugar) monitoring technology for home and clinical use, was founded in 2000 by two Israeli scientists, Company President Ron Nagar
|
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion